Which meningococcal serotypes are covered by the recommended vaccinations for patients on eculizumab?

Jun 21, 2024 ... Soliris (eculizumab) is a monoclonal antibody that's approved for patients with atypical hemolytic uremic syndrome (aHUS). It specifically works ... What side effects may I notice from receiving this medication? · Back pain · Cough · Diarrhea · Dizziness · Headache · Joint pain · Muscle pain · Nausea ... Jan 1, 2022 ... Soliris® (eculizumab) is unproven and not medically necessary for treatment of Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). Oct 3, 2024 ... - Soliris is a complement inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; atypical ... Access to Eculizumab for patients with aHUS. NHS England published NICE guidance for the use of Eculizumab for treating in aHUS in January 2015. Eculizumab inhibits complement activation and EC damage and improves renal function. ... Eculizumab? What pathophysiological model apply to secondary HUS ... This medication is given by a healthcare provider as an infusion through the vein to stop the body's immune system from attacking itself. Soliris (eculizumab) ... May 3, 2019 ... In an open-label study involving 14 patients with highly clinically active, AQP4-IgG–positive disease, the use of eculizumab reduced the frequency of relapse. Initially 900 mg once weekly for 4 weeks, then increased to 1.2 g once weekly for 1 week, followed by maintenance 1.2 g every 12–16 days, consider ... Nov 4, 2021 ... FDA approved eculizumab (SolirisTM), the only biologic treatment currently available for gMG for “adult patients who are anti-acetylcholine ...